Related Experiment Video
Updated: Jan 1, 2026
05:05
Ultrasound Cyclo Plasty in Eyes with Glaucoma
Published on: January 26, 2018
12.6K
Ocular Surface Changes in Prostaglandin Analogue-Treated Patients
Wencui Shen1, Bingqing Huang2, Jin Yang1
1Tianjin Eye Hospital & Eye Institute, Tianjin Key Laboratory of Ophthalmology and Visual Science, Nankai University, Tianjin, China.
Journal of Ophthalmology
|December 31, 2019
Summary
Prostaglandin analogues effectively lower intraocular pressure for glaucoma patients but can cause ocular surface changes. This review explores these effects and mechanisms for better clinical use.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Glaucoma is a leading cause of global blindness.
- Lowering intraocular pressure (IOP) is the primary treatment goal for glaucoma.
- Prostaglandin analogues (PGAs) are first-line treatments for lowering IOP.
Purpose of the Study:
- To review recent studies on the ocular surface changes associated with PGA use.
- To explore the potential mechanisms behind these ocular surface alterations.
- To provide insights for clinical medication considerations.
Main Methods:
- Literature review of recent studies.
- Analysis of reported ocular surface changes.
- Examination of proposed underlying mechanisms.
Main Results:
- PGAs are effective in reducing IOP.
- PGAs are associated with various ocular surface side effects.
- The exact relationship and mechanisms are complex and require further elucidation.
Conclusions:
- While PGAs are crucial for glaucoma management, their impact on the ocular surface necessitates careful monitoring.
- Understanding the mechanisms of PGA-induced ocular surface changes can guide clinical practice.
- Further research is needed to fully clarify these complex interactions.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
905
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
905
01:28Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
998
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
998
01:25Glaucoma: Overview
1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
397
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
397